AB Science Announces Positive Results of Phase 2 Study for Masitinib in COVID-19

AB Science SA released the results from its Phase 2 study evaluating masitinib in COVID-19. The study focused on hospitalized patients with moderate to severe COVID-19.

The randomized, open-label trial intended to recruit 200 patients but concluded enrollment after 95 patients due to recruitment challenges. The primary goal was to improve patients' clinical status within 15 days, monitored via the WHO 7-point ordinal scale.

The study demonstrated an odds ratio of 2.4 in favor of masitinib after 15 days, exceeding the initial hypothesis of 2.2. Sensitivity analyses at days 12, 13, and 14 showed consistent p-values and improved odds ratios, indicating the drug's efficacy.

Professor Olivier Hermine remarked on masitinib's anti-inflammatory properties and its potential as a broad antiviral agent. CEO Alain Moussy expressed gratitude to the European Investment Bank and the company's partner, Quercegen, highlighting the need for further evaluations.